Deciphera Pharmaceuticals, LLC
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING2
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO29%
Delay Index: of 7 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Deciphera Pharmaceuticals, LLC on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| INTRIGUE NCT03673501 |
P3 | Active, not recruiting | Gastrointestinal Stromal Tumors | 453 | 2021-09-01 (+3 mo) |
| MOTION NCT05059262 |
P3 | Active, not recruiting | Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis | 123 | 2023-08-10 (-7 mo) |
| Inlexisertib NCT05957367 |
P1/2 | Active, not recruiting | GIST | 94 | 2027-03 |
| INSIGHT NCT05734105 |
P3 | Active, not recruiting | GIST | 54 | 2027-12 (+22 mo) |
| DCC-3009 NCT06630234 |
P1/2 | Recruiting | Gastrointestinal Stromal Tumor (GIST) | 155 | 2028-05 |
| Vimseltinib NCT03069469 |
P1/2 | Active, not recruiting | Advanced Malignant Neoplasm; Pigmented Villonodular Synovitis | 120 | 2028-08 (+120 mo) |
| Vimseltinib NCT06619561 |
P2 | Recruiting | Chronic Graft-Versus-Host Disease (cGVHD) | 48 | 2029-10 |